Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

Alto Neuroscience, Inc.

Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. ​

Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

K2 HealthVentures

Tim Kendall

Risk and Return

What If Ventures

Windham Venture Partners

Able Partners

Apeiron Investment Group

Presight Capital

Korify Capital

Stanford University

NJF Capital

Gaingels

Alkeon Capital

Novartis Pharma

Lightswitch Capital

Sobrato Capital

Valor Equity Partners

Vine Ventures

Alpha Wave Ventures

Bioverge

InVivium Capital

Alexandria Venture Investments

Point72 Ventures

Eli Lilly

Franklin Templeton

Alto Neuroscience

To kick off this year’s #MeetTheTeam features, we’re showcasing Khanh Tang, Alto’s Associate Director of Clinical Operations. Khanh’s role is essential in reviewing data and metrics to support the oversight of current projects, as well as planning upcoming studies. When she’s not in the office, Khanh enjoys experiencing new places, cultures, and languages.


Our product candidates in development target core #brain processes, including:

🧠 Cognition
🙂 Emotion and its regulation
💤 Sleep and circadian rhythms

Learn more: https://brnw.ch/21wGjy5

#DYK that our clinical-stage pipeline includes novel drug candidates in #Depression, #PTSD, #Schizophrenia, and other #MentalHealth conditions? Learn more about our pipeline and target indications: https://brnw.ch/21wG7u9


#Psychiatry is an ever-changing field, and treatment options will continue to evolve in 2024. At Alto, we are passionate about developments in the #MentalHealth treatment landscape and furthering our mission to bring personalized, effective treatments to people in need.


Happy holidays from the Alto Team! We're planning to spend this holiday season prioritizing our mental health and spending some time with family and loved ones.


	Dec '21	Dec '22	Dec '23
account payables	600K -	1.61M 167.67%	1.07M 33.13%
accumulated other comprehensive income loss	-22K -	-46K 109.09%	-79K 71.74%
cash and cash equivalents	25.70M -	48.34M 88.07%	82.55M 70.75%
cash and short term investments	25.70M -	48.34M 88.07%	82.55M 70.75%
common stock	1K -	1K 0%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	38.16M -	81.70M 114.08%	151.34M 85.24%
long term investments
net debt	12.46M -	33.76M 171.01%	68.92M 104.12%
net receivables	1.74M -	546K 68.67%	8K 98.53%
other assets	1 -		1 -
other current assets	236K -	330K 39.83%	2.83M 759.09%
other current liabilities	1.21M -	3.67M 203.39%	4.41M 20.16%
other liabilities	1 -
other non current assets	50.00K -	55K 10.00%	131.00K 138.18%
other non current liabilities	1.30M -	2M 53.96%	1.35M 32.40%
othertotal stockholders equity	493K -	2.30M 366.33%	4.02M 74.86%
preferred stock			1.35M -
property plant equipment net	1.06M -	1.58M 48.96%	1.11M 29.96%
retained earnings	-12.95M -	-40.66M 213.98%	-76.97M 89.29%
short term debt		283K -	125K 55.83%
short term investments
tax assets
tax payables
total assets	28.79M -	50.85M 76.61%	86.63M 70.35%
total current assets	27.68M -	49.22M 77.79%	85.39M 73.49%
total current liabilities	1.81M -	5.56M 207.18%	5.61M 0.90%
total debt	38.16M -	82.11M 115.15%	151.46M 84.47%
total investments
total liabilities	41.27M -	89.26M 116.27%	158.30M 77.35%
total liabilities and stockholders equity	28.79M -	50.85M 76.61%	86.63M 70.35%
total non current assets	1.11M -	1.63M 47.21%	1.24M 24.30%
total non current liabilities	39.46M -	83.70M 112.10%	152.69M 82.43%
total stockholders equity	-12.48M -	-38.41M 207.79%	-71.67M 86.62%

ANRO

COM:ALTONEUROSCIENCE

Alto Neuroscience

Last Close

4.09

22/11 21:00

Market Cap

338.20M

Beta: -

Volume Today

362.06K

Avg: -

Preview